Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Initial results from a phase 2 study of cladribine, cytarabine, and granulocyte-colony stimulating factor with gemtuzumab ozogamicin (CLAG-GO) for the treatment of patients with relapsed/refractory acute myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

DCDung‐Tsa ChenVSVivek M. ShastriSBSøren M. Bentzen

Discussion

Loading...

Member takes

Overview

Single-arm phase 2 trial reports 42% response rate in 19 adults with relapsed acute myeloid leukemia, indicating safety of cladribine and gemtuzumab ozogamicin.

Key Points

  • Response rate reached 42%, with 36% achieving complete remission and no toxicity increase from gemtuzumab.
  • Median overall survival was recorded as 9.53 months, highlighting effectiveness in relapsed acute myeloid leukemia.
  • Single-arm phase II trial evaluated efficacy and safety of cladribine and granulocyte-colony stimulating factor alongside gemtuzumab.
  • Findings suggest potential for using CD33 expression to guide treatment decisions and salvage therapy outcomes.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e393https://doi.org/10.1182/blood-2025-999
View Full Paper
Ask AI
Bookmark
Share